Genmab — Februar 2016
-
MYELOMA INTERGROUP FRANCOPHONE DU in collaboration with Janssen initiated another phase III trial to evaluate daratumumab in combination with bortezomib, thalidomide and dexamethasone, as front-line therapy in approximately 1080 patients with multiple myeloma who are candidates for stem cell transplantation (IFM 2015-01; HO131; 54767414MMY3006; EudraCT2014-004781-15; NCT02541383). The trial will be conducted in collaboration with the and the Dutch-Belgian Cooperative Trial Group for Haematology
-
Det er et imponerende udsalg de anonyme har gang i - i dag sælger de endda mere end i går
-
din bias er lidt negativ OHW

-
det bliver i hvert fald svært at stikke den spænding aktien har leveret siden nytår...
-
Flot start af NBI + 2%
-
med hensyn til recepter og off label i combo, jeg tror det kommer til brede sig som ringe i vandet læs kommentar 2 i indlæget http://www.myelomabeacon.com/forum/daratumumab-and-eliquis-t6784.html
-
Jan har altid overrasket og gjort et fantastisk stykke arbejde.. Ingen bekymringer mht til imorgen herfra

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind